Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
How this flexicap mutual fund turned Rs 1 lakh to Rs 34 lakh in 22 years
1er/10/2025
Gold hovers near record high on US shutdown concerns, Fed rate outlook
1er/10/2025
Can October deliver gains for equity investors amidst market constraints ?
1er/10/2025
LG Electronics to launch Rs 11,500 crore IPO on October 7
1er/10/2025
MS, Goldman, Amansa among companies eyeing Tata Capital anchor book
1er/10/2025
Axis Bank reassessing plan to sell stake in Axis Finance
1er/10/2025
